HUMANIGEN - BUY | USD30 (+151%) After Jakafi’s failure, eyes turn on lenzilumab to deliver data in Q1 2021
Phase III enrolment is on track for a readout in Q1 2021Jakafi’s miss to combat cytokine storm turns heads to anti-GM-CSF
Anti-GM-CSF agents in a good position to play central role in the treatment of covid-19
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.